Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Calliditas Therapeutics in connection with a directed share issue
Mandate

Vinge advises Calliditas Therapeutics in connection with a directed share issue

August 17, 2021 Capital Markets and Public M&A

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with a directed share issue whereby the company will raise proceeds of approximately SEK 324 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Benjamin Vafaeian.

Related

Vinge advises the financing banks in connection with Verdane and Telenor’s partnership in Telenor Connexion

 Vinge has advised a syndicate of Nordic and Northern European banks connection with the financing of Verdane and Telenor’s new partnership relating to Telenor Connexion. Under the partnership, Verdane and Telenor will jointly invest in Telenor Connexion, a leading provider of IoT solutions. The transaction was completed on 10 September 2026 and values Telenor Connexion at SEK 7.5 billion.
September 23, 2026

Vinge advises Accru Partners on its EUR 550 million senior secured bond issuance

 Vinge advises Accru Partners, backed by Axcel, in connection with Accru Partners’ inaugural EUR 550 million issuance of senior secured bonds.
September 23, 2026

Vinge advises Sveafastigheter on EUR 350 million bond issuance

 Vinge has advised Sveafastigheter AB (publ) on the issuance of EUR 350 million in senior unsecured bonds under its existing EUR 2 billion EMTN programme.
September 23, 2026